NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Nope.

One other thing I observed, probably completely unrelated, was

CTO (confidential treatment order) filed with SEC for ARGS (Argos Therapeutics) in mid December 2016. Still not explained to my knowledge.

Two board members voluntarily resigned at ARGS on December 9, 2017. Both happened to be on the compensation committee. No apparent reason for resignation.

CEO Jeff Abbey signed 40 thousand square foot lease in North Carolina mid January 2017, one month after the board resignations and CTO (confidential treatment order) and one month before trial failure.

On January 23, 2017, the company no longer marked that it was in an FDA regulated trial in clinicaltrials.gov.

On February 6, 2017, the company CEO Jeff Abbey gave an interview to Seeking Alpha blogger just before AGS-003 failed in its phase III trial, and admitted that the last patient was enrolled in mid October 2015 (ARGOS ARGS had initially PR'd in mid July 2015 that they completed enrollment.) A lot of small Board stock purchases in October 2016.

Oh, and on February 6, 2017, the partial hold on the NWBO's phase iii DCVax-L trial was lifted.

On February 22, 2017, ARGS announced the phase III trial failed due to futility without providing any statistical and/or data details.

Also on February 22, 2017, AGEN "quietly" announced its phase III GBM trial failure.

I have no idea what all that means. Perhaps just lots of coincidences, typos and such.